Explore the words cloud of the P-TEV project. It provides you a very rough idea of what is the project "P-TEV" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||2˙184˙603 €|
|EC max contribution||2˙184˙603 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-09-01 to 2019-08-31|
Take a look of project's partnership.
This project will commercialize P-TEV - a unique personalized tissue engineered vein for the treatment of patients with severe Chronic Venous Insufficiency (CVI). CVI is a progressive medical condition in which the valves of the deep veins of the leg are not functioning properly. The most severe stage is CVI with leg ulceration. No effective treatment is available, and a large number of patients would directly benefit from venous vascular surgery. These patients cannot be cured today because no suitable grafts for replacement of the dysfunctional venous valves have yet been developed. There are no synthetic products which could replace the function of the bicuspid valves found in the leg veins and the risks associated with allotransplantation are too high. VERIGRAFT’s technology is the first one positioned to break this paradigm and fill the existing market gap. The technology allows the personalization of blood vessels by de- and recellularization. In short, a donated tissue is decellularized, removing all immunogenic donor cells and DNA. This results in a clean extracellular matrix scaffold with intact 3D structural properties. Subsequently, this scaffold is seeded with the patient´s own cells, derived from a small sample of peripheral blood. This unique technology turns an allogeneic (“foreign”) tissue into an autologous (“personalized”) one and thus avoids transplant rejection without the need for immunosuppression. The clinical proof-of-concept for P-TEV is established. The project will include the clinical study and GMP process development that will grant VERIGRAFT market access by 2019 and serve as a steppingstone to marketing approval by the European Medicines Agency. The EU-added value of the project is unparalleled, as it constitutes a breakthrough in one of future medicine's most promising fields – advanced personalized regenerative medicine, bringing significant long-term budgetary relief to healthcare systems.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "P-TEV" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "P-TEV" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More